Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 359

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer

Open access
Kang, Yoon-Koo, Yook, Jeong Hwan, Park, Young-Kyu, Lee, Jong Seok, Kim, Young-Woo, Kim, Jin Young, Ryu, Min-Hee, Rha, Sun Young, Chung, Ik Joo, Kim, In-Ho, Oh, Sang Cheul, Park, Young Soo, Son, Taeil, Jung, Mi Ran, Heo, Mi Hwa, Kim, Hark Kyun, Park, ChoHyun, Yoo, Chang Hak, Choi, Jin-Hyuk, Zang, Dae Young, Jang, You Jin, Sul, Ji Young, Kim, Jong Gwang, Kim, Beom Su, Beom, Seung-Hoon, Cho, Sang Hee, Ryu, Seung Wan, Kook, Myeong-Cherl, Ryoo, Baek-Yeol, Kim, Hyun Ki, Yoo, Moon-Won, Lee, Nam Su, Lee, Sang Ho, Kim, Gyunji, Lee, YeonJu, Lee, Jee Hyun, Noh, Sung Hoon·2021·Journal of Clinical Oncology

Abstract

PURPOSE: Adjuvant chemotherapy after D2 gastrectomy is standard for resectable locally advanced gastric cancer (LAGC) in Asia. Based on positive findings for perioperative chemotherapy in European phase III studies, the phase III PRODIGY study (ClinicalTrials.gov identifier: NCT01515748 ) investigated whether neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) followed by surgery and adjuvant S-1 could improve outcomes versus standard treatment in Korean patients with resectable LAGC. PATIENTS AND METHODS: Patients 20-75 years of age, with Eastern Cooperative Oncology Group performance status 0-1, and with histologically confirmed primary gastric or gastroesophageal junction adenocarcinoma (clinical TNM staging: T2-3N+ or T4Nany) were randomly assigned to D2 surgery followed by adjuvant S-1 (40-60 mg orally twice a day, days 1-28 every 6 weeks for eight cycles; SC group) or neoadjuvant DOS (docetaxel 50 mg/m 2, oxaliplatin 100 mg/m 2 intravenously day 1, S-1 40 mg/m 2 orally twice a day, days 1-14 every 3 weeks for three cycles) before D2 surgery, followed by adjuvant S-1 (CSC group). The primary objective was progression-free survival (PFS) with CSC versus SC. Two sensitivity analyses were performed: intent-to-treat and landmark PFS analysis. RESULTS: Between January 18, 2012, and January 2, 2017, 266 patients were randomly assigned to CSC and 264 to SC at 18 Korean study sites; 238 and 246 patients, respectively, were treated (full analysis set). Follow-up was ongoing in 176 patients at data cutoff (January 21, 2019; median follow-up 38.6 months [interquartile range, 23.5-62.1]). CSC improved PFS versus SC (adjusted hazard ratio, 0.70; 95% CI, 0.52 to 0.95; stratified log-rank P = .023). Sensitivity analyses confirmed these findings. Treatments were well tolerated. Two grade 5 adverse events (febrile neutropenia and dyspnea) occurred during neoadjuvant treatment. CONCLUSION: PRODIGY showed that neoadjuvant DOS chemotherapy, as part of perioperative chemotherapy, is effective and tolerable in Korean patients with LAGC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.20.02914

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 359

Metadata

Authors
Kang, Y.-K., Yook, J. H., Park, Y.-K., Lee, J. S., Kim, Y.-W., Kim, J. Y., Ryu, M.-H., Rha, S. Y., Chung, I. J., Kim, I.-H., Oh, S. C., Park, Y. S., Son, T., Jung, M. R., Heo, M. H., Kim, H. K., Park, C., Yoo, C. H., Choi, J.-H., Zang, D. Y., Jang, Y. J., Sul, J. Y., Kim, J. G., Kim, B. S., Beom, S.-H., Cho, S. H., Ryu, S. W., Kook, M.-C., Ryoo, B.-Y., Kim, H. K., Yoo, M.-W., Lee, N. S., Lee, S. H., Kim, G., Lee, Y., Lee, J. H., & Noh, S. H.
Venue
Journal of Clinical Oncology
Published
2021-09-10
Volume
39
Issue
26
Pages
2903-2913
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W3166801653
Cited by
359
References
19
FWCI
30.64
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. https://app.cochat.ai/papers/10.1200/jco.20.02914
The paper
Kang, Y.-K., Yook, J. H., Park, Y.-K., Lee, J. S., Kim, Y.-W., Kim, J. Y., Ryu, M.-H., Rha, S. Y., Chung, I. J., Kim, I.-H., Oh, S. C., Park, Y. S., Son, T., Jung, M. R., Heo, M. H., Kim, H. K., Park, C., Yoo, C. H., Choi, J.-H., . . . Noh, S. H. (2021). PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.20.02914

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.